Treatment Candidacy for Pharmacologic Therapies for NASH-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Candidacy for Pharmacologic Therapies for NASH

Published:2021-03 Issue: Volume: Page:
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Rowe Ian A.,Wong Vincent Wai-Sun,Loomba Rohit

Funder

Boehringer Ingelheim

National Center for Advancing Translational Sciences

U.S. Department of Defense

Allergan

NHLBI

Gilead UK and Ireland Corporate Contributions

National Institute of Environmental Health Sciences

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference65 articles.

1. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis;Younossi;Hepatology,2019

2. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease;Eslam;Gastroenterology,2020

3. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies;Singh;Clin Gastroenterol Hepatol,2015

4. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates;Younossi;Clin Gastroenterol Hepatol,2019

5. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis;Li;Lancet Gastroenterol Hepatol,2019

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease;Frontiers in Medicine;2024-07-31

2. The efficacy and safety of Dachaihu decoction in the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis;Frontiers in Medicine;2024-07-02

3. Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis;Alimentary Pharmacology & Therapeutics;2024-01-31

4. Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century;Annals of Hematology;2024-01-16

5. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon;Current Hepatology Reports;2024-01-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3